What are biomarkers asessed in diagnosis of Orofacial pain conditions?
What is the quality and level of evidence on biomarkers for orofacial pain conditions?
Patients diagnosed with Orofacial pain AND
i. Age > 18 years
ii. A diagnosis of Orofacial pain.
Conditions that can influence pain sensitivity, such as systemic inflammatory connective tissue diseases (e.g., rheumatoid arthritis); whiplash-associated disorders; chronic widespread muscle pain conditions (e.g., fibromyalgia); neuropathic pain or neurological disorders (e.g., oromandibular dystonia); pain of dental origin; pregnancy or lactation; high blood pressure; and ongoing dental treatment. Another exclusion criterion is medication that could interfere with the blood analysis or pain sensitivity (e.g., anticoagulant treatment and analgesic consumption within 1 week before the experiment, for example, of paracetamol, NSAIDs (Non-steroidal anti-inflammatory drugs), salicylate drugs, or opioids) or that could influence pain perception (e.g., anti-depressants or antiepileptic drugs). Exclusion criteria will be assessed in each subject by taking a medical history.
Standard ora-facial conditions assessment includes clinical assessment.
The exposure reviewed will be the presence of biomarkers in any of the body fluids, in patients who have been diagnosed with Orofacial pain.
To determine the most potential and specific biomarkers for Orofacial pain.